ストックスクリーナーアプリを入手
4.81
3.22%
-0.16
前日終値:
$4.97
開ける：
$4.91
24時間の取引高:
29,208
Relative Volume:
0.43
時価総額：
$15.43M
収益：
-
当期純損益:
$-45.52M
株価収益率:
-0.4945
EPS:
-9.7265
ネットキャッシュフロー:
$-31.51M
1週間 パフォーマンス:
-15.76%
1か月 パフォーマンス:
-40.47%
6か月 パフォーマンス:
-27.56%
1年 パフォーマンス:
+1,118%
1日の値動き範囲:
$4.7027
$5.01
1週間の範囲:
$4.7027
$5.82
52週間の値動き範囲:
$0.257
$20.00
Passage Bio Inc Stock (PASG) Company Profile
名前
Passage Bio Inc
セクター
電話
(267) 866-0312
住所
ONE COMMERCE SQUARE, PHILADELPHIA, PA
Compare PASG vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
PASG
Passage Bio Inc
|
4.81 | 15.94M | 0 | -45.52M | -31.51M | -9.7265 |
VRTX
Vertex Pharmaceuticals Inc
|
427.20 | 107.83B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
707.69 | 73.54B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
803.75 | 48.72B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
293.59 | 39.51B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
299.31 | 32.66B | 5.36B | 287.73M | 924.18M | 2.5229 |
Passage Bio Inc Stock (PASG) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-04-21 | ダウングレード | Chardan Capital Markets | Buy → Neutral |
| 2026-04-21 | ダウングレード | TD Cowen | Buy → Hold |
| 2026-04-21 | ダウングレード | Wedbush | Outperform → Neutral |
| 2026-03-31 | 開始されました | Oppenheimer | Outperform |
| 2026-02-10 | 再開されました | Chardan Capital Markets | Buy |
| 2024-11-29 | 再開されました | Wedbush | Outperform |
| 2024-09-03 | 開始されました | Rodman & Renshaw | Buy |
| 2022-03-08 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2022-01-19 | ダウングレード | Goldman | Buy → Neutral |
| 2021-07-01 | 開始されました | Raymond James | Outperform |
| 2021-06-15 | 開始されました | BTIG Research | Buy |
| 2021-03-04 | アップグレード | Goldman | Neutral → Buy |
| 2021-02-04 | 開始されました | Guggenheim | Buy |
| 2021-01-25 | 開始されました | Wedbush | Outperform |
| 2021-01-04 | アップグレード | JP Morgan | Neutral → Overweight |
| 2020-12-11 | 開始されました | Citigroup | Neutral |
| 2020-08-14 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2020-06-25 | ダウングレード | Goldman | Buy → Neutral |
| 2020-03-25 | 開始されました | Chardan Capital Markets | Buy |
| 2020-03-24 | 開始されました | Cowen | Outperform |
| 2020-03-24 | 開始されました | Goldman | Buy |
| 2020-03-24 | 開始されました | JP Morgan | Overweight |
すべてを表示
Passage Bio Inc (PASG) 最新ニュース
Passage Bio Announces Major Workforce Reduction and Restructuring - TipRanks
Passage Bio (NASDAQ: PASG) slashes workforce by 75% in 2026 restructuring - Stock Titan
Passage Bio Reports Trial Data, Reviews Strategic Options - MyChesCo
Chardan Capital Maintains Passage Bio (PASG) Buy Recommendation - MSN
Canaccord Genuity Remains a Buy on Passage Bio (PASG) - The Globe and Mail
PASG Maintains Rating by Oppenheimer -- Price Target Lowered to $15 - GuruFocus
PASG Downgraded by Chardan Capital -- Price Target Lowered to $7 - GuruFocus
Passage Bio (PASG) Downgraded by Wedbush Analyst - GuruFocus
PASG Downgraded by TD Cowen -- Rating Changed to Hold - GuruFocus
Passage Bio Faces Tougher FDA Road After Trial Shift, Wedbush Says - marketscreener.com
PASG Downgraded by Wedbush -- Price Target Lowered to $8.00 - GuruFocus
Passage Bio Seen as Undervalued Despite FDA Setback, Oppenheimer Says - marketscreener.com
Passage Bio downgraded to Neutral from Buy at Chardan - TipRanks
This Mohawk Industries Analyst Is No Longer Bullish; Here Are Top 2 Downgrades For Tuesday - Benzinga
Passage Bio stock rating cut to Hold by TD Cowen on FDA trial news - Investing.com South Africa
Oppenheimer Adjusts Price Target on Passage Bio to $15 From $30, Maintains Outperform Rating - marketscreener.com
Wedbush Downgrades Passage Bio to Neutral From Outperform, Cuts Price Target to $8 From $32 - marketscreener.com
Oppenheimer cuts Passage Bio stock price target on regulatory setback - Investing.com
Oppenheimer cuts Passage Bio stock price target on regulatory setback By Investing.com - Investing.com Australia
Passage Bio Announces PBFT02 Data and Strategic Review - The Globe and Mail
Chardan Downgrades Passage Bio to Neutral From Buy, Cuts Price Target to $7 From $21 - marketscreener.com
Chardan downgrades Passage Bio stock rating on strategic review By Investing.com - Investing.com South Africa
Chardan downgrades Passage Bio stock rating on strategic review - Investing.com
Passage Bio to Present at H.C. Wainwright Global Investment Conference - MSN
Wedbush Maintains Passage Bio(PASG.US) With Buy Rating, Maintains Target Price $32 - Moomoo
New Developments for Passage Bio (PASG) in Frontotemporal Dement - GuruFocus
Is Passage Bio (PASG) stock safe today (Underperforming) 2026-04-20Viral Momentum Stocks - Xã Thanh Hà
Lucid downgrades Passage Bio stock rating on funding concerns By Investing.com - Investing.com South Africa
Lucid downgrades Passage Bio stock rating on funding concerns - Investing.com
Passage Bio Starts Strategic Review After FDA Doesn't Support Single-Arm Trial - Moomoo
Passage Bio Reports Positive Interim Data for PBFT02 in FTD-GRN, Initiates Strategic Review After FDA Guidance 1 - Minichart
Passage Bio reports biomarker improvements in FTD trial - Investing.com
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
Passage Bio reports biomarker improvements in FTD trial By Investing.com - Investing.com Canada
Passage Bio Reports Updated Interim Data from upliFT-D Trial and Provides Regulatory and Corporate Updates - The Manila Times
Gene therapy company Passage Bio, Inc. recently disclosed two major decisions: the official appointment of Wedbush Pacgrow as its financial advisor, and the commencement of a comprehensive evaluation of strategic alternatives. - Bitget
Strategic review at Passage Bio (NASDAQ: PASG) after FDA trial guidance - Stock Titan
Leading Companies Fueling Innovation and Growth in the GM1 Gangliosidosis Market - openPR.com
Short Squeeze: What is the earnings history of Passage Bio IncTrade Entry Report & Consistent Profit Focused Trading Strategies - baoquankhu1.vn
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
PMN Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Trends in Growth, Segment Analysis, and Competitive Strategies Influencing the Adeno-Associated Viral Vectors Market - openPR.com
PASG PE Ratio & Valuation, Is PASG Overvalued - Intellectia AI
Passage Bio Inc (PASG) 財務データ
収益
当期純利益
現金流量
EPS
0.83%
2.04%
大文字化:
|
ボリューム (24 時間):